Redefining the therapeutic objective in psoriatic patients candidates for biological therapy.

about

Redefining the therapeutic objective in psoriatic patients candidates for biological therapy.

Item

http://www.wikidata.org/entity/Q48368354

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Redefining the therapeutic obj ...... idates for biological therapy.

@en

Redefining the therapeutic obj ...... idates for biological therapy.

@nl

type

Item

label

Redefining the therapeutic obj ...... idates for biological therapy.

@en

Redefining the therapeutic obj ...... idates for biological therapy.

@nl

prefLabel

Redefining the therapeutic obj ...... idates for biological therapy.

@en

Redefining the therapeutic obj ...... idates for biological therapy.

@nl

P1476

Redefining the therapeutic obj ...... didates for biological therapy

@en

P2093

A López-Ferrer

http://www.w3.org/2001/XMLSchema#string

C Soria

http://www.w3.org/2001/XMLSchema#string

E Vilarrasa

http://www.w3.org/2001/XMLSchema#string

F Peral

http://www.w3.org/2001/XMLSchema#string

G Carretero

http://www.w3.org/2001/XMLSchema#string

I Belinchon

http://www.w3.org/2001/XMLSchema#string

J L Sánchez-Carazo

http://www.w3.org/2001/XMLSchema#string

J Mitxelena

http://www.w3.org/2001/XMLSchema#string

J Vilar-Alejo

http://www.w3.org/2001/XMLSchema#string

L Ferrándiz

http://www.w3.org/2001/XMLSchema#string

P2860

Definition of treatment goals for moderate to severe psoriasis: a European consensus

A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases

Global epidemiology of psoriasis: a systematic review of incidence and prevalence

Drug Survival Studies in Dermatology:Principles, Purposes, and Pitfalls

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.

Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.

Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting.

Adherence and resource use among patients treated with biologic drugs: findings from BEETLE study

P304

334-346

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/09546634.2017.1395794

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ricardo Ruiz Villaverde

Luis Puig

Susana Armesto

José Manuel Carrascosa

P577

2017-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29099667

http://www.w3.org/2001/XMLSchema#string